9 citations
,
January 2014 in “Annals of Dermatology” In this report, five female patients undergoing hormonal anticancer therapy for breast cancer prevention developed pattern alopecia, which the authors attribute to androgen-estrogen imbalance caused by antiestrogenic drugs.
4 citations
,
November 2022 in “BMC Women s Health” This study found that Sudanese breast cancer survivors receiving hormonal or HER2-targeted therapies had better quality of life compared to those on conventional therapy.
5 citations
,
January 2024 in “Egyptian Dental Journal /Egyptian Dental Journal” This study discusses various anti-cancer therapies, including chemotherapy and immunotherapy, emphasizing the challenges in classifying these medications due to their diverse chemical compositions, mechanisms of action, and effectiveness against different types of cancer.
June 2025 in “British Journal of Clinical Pharmacology” This study highlights the significant impact of cutaneous side effects associated with anticancer therapies, emphasizing the need for proactive management to improve patient quality of life and treatment adherence.
31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.
